Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
June 20, 2019 07:30 ET
|
Arbutus Biopharma Corporation
- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral...
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
June 17, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the...
Arbutus to Participate at JMP Securities Life Sciences Conference
June 13, 2019 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus to Present at Upcoming May 2019 Conferences
May 13, 2019 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 06, 2019 16:01 ET
|
Arbutus Biopharma Corporation
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and...
Arbutus to Report First Quarter 2019 Financial Results
April 29, 2019 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
March 07, 2019 16:01 ET
|
Arbutus Biopharma Corporation
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available...
Arbutus to Present at Cowen Health Care Conference
March 04, 2019 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update
February 28, 2019 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
November 26, 2018 16:41 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....